<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT01726699</url>
  </required_header>
  <id_info>
    <org_study_id>12-6011</org_study_id>
    <nct_id>NCT01726699</nct_id>
  </id_info>
  <brief_title>Scripps Tumorgraft Study</brief_title>
  <official_title>Scripps Tumorgraft Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scripps Translational Science Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Scripps Translational Science Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study the genetic traits of cancerous tissues and to help improve cancer treatment by&#xD;
      developing tumor models for studying new cancer drugs.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">July 2014</completion_date>
  <primary_completion_date type="Actual">July 2014</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Facilitate the development of individualized tumorgraft models for many different types of cancer.</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">11</enrollment>
  <condition>Solid Tumor Malignancy or Hematologic Malignancy</condition>
  <arm_group>
    <arm_group_label>Cancer Diagnosis</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood and tissue samples&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Adults with a solid tumor malignancy or a hematologic malignancy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 21 or over&#xD;
&#xD;
          -  diagnosis of a solid tumor malignancy, either resectable or metastatic or a&#xD;
             hematologic malignancy&#xD;
&#xD;
          -  cognitively and emotionally able to give informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Under age 21&#xD;
&#xD;
          -  Not cognitively or emotionally able to give informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Goetz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Director, Applied Genetic Epidemiology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Scripps Translational Science Institute</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>November 6, 2012</study_first_submitted>
  <study_first_submitted_qc>November 9, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2012</study_first_posted>
  <last_update_submitted>April 1, 2015</last_update_submitted>
  <last_update_submitted_qc>April 1, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Scripps Translational Science Institute</investigator_affiliation>
    <investigator_full_name>Eric Topol, MD</investigator_full_name>
    <investigator_title>Director, Applied Genetic Epidemiology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Hematologic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT01726699
org study id: 12-6011
nct id: NCT01726699
lead sponsor: 
has dmc: No
Study the genetic traits of cancerous tissues and to help improve cancer treatment by
      developing tumor models for studying new cancer drugs.
observational model: Case-Only
time perspective: Prospective
measure: Facilitate the development of individualized tumorgraft models for many different types of cancer.
time frame: 3 years
arm group label: Cancer Diagnosis
Blood and tissue samples
study pop: 
sampling method: Probability Sample
criteria: 
gender: All
minimum age: 21 Years
maximum age: N/A
healthy volunteers: No
last name: Laura Goetz, MD
role: Principal Investigator
affiliation: Director, Applied Genetic Epidemiology
facility: 
country: United States
responsible party type: Principal Investigator
investigator affiliation: Scripps Translational Science Institute
investigator full name: Eric Topol, MD
investigator title: Director, Applied Genetic Epidemiology
mesh term: Neoplasms
mesh term: Hematologic Neoplasms